Attralus Receives FDA Orphan Drug Designation for Zamubafusp Alfa in AL Amyloidosis

FDA Grants Orphan Drug Designation to Zamubafusp Alfa

Attralus, a clinical-stage biopharmaceutical company focused on systemic amyloidosis, has announced an important regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zamubafusp alfa (AT-02) for the treatment of immunoglobulin light-chain-associated (AL) amyloidosis.

This designation highlights the potential of zamubafusp alfa as a treatment option for a rare and serious disease that currently has limited therapeutic choices available for patients.